Last checked at 14 Aug 2018 07:15
Hardman & Co Research Hardman & Co Research: Oxford BioMedica (OXB): Risk-sharing in cystic fibrosis gene-therapy 14-Aug-2018 / 07:15 GMT/BST Hardman & Co: Risk-sharing in cystic fibrosis gene-therapy OXB is a specialist, advanced-therapy, lentivirus vector biopharma company. It offers vector manufacturing and development services and has a proprietary drug pipeline. In addition to LentiVector(R) service contracts, OXB receives royalties on commercial therapies developed by its partners using the LentiVector platform. A partnership deal structure was established with Novartis for KymriahPPPTM in 2017,PP followed by a collaboration with Bioverativ in February 2018 and by out-licensing its Parkinson's disease gene-therapy to Axovant in June 2018. In August, OXB announced a second 2018 collaboration agreement, for cystic fibrosis gene-therapy. Please click here for the full report: http://hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/14.08.18-risk-sharing-in-cystic-fibrosis-gene-therapy.pdf
Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement. About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer. Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement. |
713805 14-Aug-2018
corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.